Has Homam Ibrahim, MD received payments from drug or device companies?

Yes. Drug and device makers reported $49,405 in general payments to Homam Ibrahim, MD across 269 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Homam Ibrahim, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Homam Ibrahim, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Homam Ibrahim, MD

Interventional Cardiology · Silver Spring, MDNPI 1114150257

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (50.5%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Medtronic accounts for 77.8% of it on its own, with 19 other manufacturers making up the rest. Reporting peaked in 2024 at $23,033 and has fallen 85.0% since, to $3,454 in 2025.

$49,405in general payments, 2019–2025

Across 269 payments — averaging $183.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Medtronic$38K
Abbott$6K
Edwards Lifesciences$2K
Boston Scientific$2K
Shockwave Medical, Inc$388
Janssen Scientific Affairs, LLC$373
plus $941 from 14 others

$29,325in research payments, 2019–2025

Across 2 payments — averaging $14,662 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Novartis$27K
Medtronic$2K

What the payments were for

Speaking & faculty fees$24,96351%
Travel & lodging$10,90822%
Food & beverage$13,25327%
Other$2821%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Medtronic(2 entities)	149	$38,459
Abbott	55	$5,854
Edwards Lifesciences	27	$1,822
Boston Scientific	9	$1,568
Shockwave Medical, Inc	4	$388
Janssen Scientific Affairs, LLC	3	$373
Chiesi USA, Inc.	2	$238
Abiomed	1	$167
Philips North America LLC	2	$133
Pfizer	2	$56
Supreme Orthopedic Systems, LLC	2	$48
Novartis	2	$48
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)	2	$46
Boehringer Ingelheim	2	$45
AstraZeneca	2	$43
E.r. Squibb & Sons, L.L.C.	1	$32
Daiichi Sankyo Inc.	1	$28
Novo Nordisk	1	$23
Kiniksa Pharmaceuticals International, PLC	1	$19
Atricure, Inc.	1	$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

COREVALVE EVOLUT R$26,808
CoreValve Evolut$6,307
Mitra Clip system$1,625
Avalus$1,302
WATCHMAN Access System$1,173
TRICLIP$1,102
MitraClip$872
MitraClip System$455
XARELTO$373
Xience Sierra Coronary Stent$372
Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$303
IN.PACT Admiral$300
PORTICO$282
HawkOne$226
PASCAL$190
Impella$167
(9520) IGT Devices Undivided$120
Watchman$119
KENGREAL 50MG/10ML L$119
KENGREAL$119

How this compares

$49,405 in reported general payments places this provider in the 85th percentile of 71 interventional cardiology providers in Maryland.

See all interventional cardiology providers in Maryland →

Medicare billing

Part B allowed, 2024

$139,076

Medicare patients

240

Services billed

829

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Losartan Potassium	21	$222
Spironolactone	13	$211
Metoprolol Succinate	11	$177

Paid to pharmacies, not to this prescriber.

Other interventional cardiology in Silver Spring

Eric LiebermanSilver Spring$7K
Vinay SatwahGreenbelt$679K
Aloke FinnBaltimore$575K
Michael ChenRockville$241K
John WangBaltimore$138K
Steven HearneSalisbury$100K
Amir NajafiBel Air$82K
Diljon ChahalBaltimore$78K
Joseph CinderellaSalisbury$72K
Ali TabrizchiBel Air$66K

See the full list for Maryland →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →